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Abstract 
 
A low prevalence of smokers among the confirmed patients with COVID-19 has 
been reported by multiple hospital-based studies, and this observation gave rise to 
a hypothesis that smoking has a protective effect against the novel coronavirus. 
We test this prediction in a population-based study across the US states and use 
an instrumental variable approach to address the endogeneity of smoking rates. 
We find that a higher prevalence of smoking has a significant negative effect on 
the spread and the severity of the COVID-19 pandemic across the US state: it 
decreases the per capita number of registered cases, the case fatality rate, and the 
excess mortality. The protective effect is more pronounced in subgroups of the 
population that are more likely to be smokers: men of all ages and females of the 
older cohort. Our findings are robust to the inclusion of a broad range of control 
variables, exclusion of outliers, and placebo tests. Despite the protective effect 
against the COVID-19, smoking remains detrimental for health in the long-term, 
and we show that states with a higher rate of smoking also have higher mortality 
in the year before the outbreak. 
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1 Introduction 
 
This paper investigates a major puzzle posed by the global pandemic regarding a potentially 
protective effect of smoking against the novel coronavirus decease (COVID -19). From the very 
start of the outbreak, smoking was considered to be a major risk factor both for infection spread 
and severity of the COVID-19 illness (e.g., Brake et al. 2020). This expectation was rooted in 
the previous research that finds smokers to be significantly more vulnerable to the respiratory 
deceases in general (e.g., Bello et al. 2014). However, it was soon observed that the prevalence 
of smokers hospitalized with COVID-19 was considerably lower compared to the smoking rate 
in the general population. This finding was confirmed using data on hospitalized patients in 
China (Arsalan’s et al. 2020a), the United States (Chow et al. 2020; Petrilli et al. 2020), France 
(Miyara et al. 2020), and Italy (Gonzalez-Rubio et al. 2020). The difference in the prevalence 
of smokers hospitalized with COVID-19 is not only consistent across countries but also 
substantial in its magnitude: for example, Farsalinos et al. (2020a) estimate it to be 
approximately one-fourth of the expected gender-adjusted smoking prevalence in China.1 If 
correct, this regularity would imply a protective effect of smoking against COVID-19 that 
might be the key to developing an effective therapy for the decease. Yet, the current evidence 
is grounded exclusively in hospital-based studies that suffer from limitations such as data 
quality, sampling bias, and, consequently, low external validity, and further research requires 
well-designed population-based studies (WHO 2020).  
We answer this call by providing an econometric study of the relationship between the 
spread and mortality from COVID-19 and smoking across the US states. The USA represents 
about 30% of the world’s registered COVID-19 cases and deaths. The ample heterogeneity in 
the spread and severity of the pandemic across the states provides a unique empirical setting 
for our analysis. We evaluate the relationship between the three main statistics of the COVID-
19 epidemic, such as the number of infections, the case fatality rate (CFR), and the excess 
mortality, and smoking prevalence across the US states. Because smoking rates in the 
 
1 The more recent study by Farsalinos et al. (2020b) includes additional data from the USA and South 
Korea and finds the prevalence of smokers to be even smaller: about one-fifth of prevalence in 
corresponding national population. 
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population are endogenous, we apply the instrumental variables approach (IV). We take 
advantage of the state-to-state diffusion of anti-smoking policies (e.g., French and Popovici 
2011) and show that higher past state-taxes on cigarettes in the neighboring states are a strong 
predictor of lower rates of smoking and cigarette consumption. Our main findings are the 
significant negative effects of smoking on the spread of the COVID-19 and its fatality in terms 
of the CFR and population fatality rate (PFR) approximated by the excess mortality. The 
magnitude of the effect is substantial: 1 percentage point increase in smoking leads to a 
reduction in infection incidents, the CFR, and the PFR by 0.3, 1, and 0.8 percentage points, 
respectively. We further look at the age and gender composition of deaths from COVID-19 and 
find that the protective effect is robust among the adult male population irrespective of age. 
In the female population, the protective effect of a similar size is detected only for women older 
than 65 years, and there is no effect for women younger than 65 because of a relatively lower 
smoking rate in this age group (Department of Health and Human Services 2001). Despite the 
protective effect against the novel coronavirus, smoking is deadly, as we demonstrate in the 
analysis of the mortality rate across the US state in the year before the pandemic. Finally, our 
results are robust to the exclusion of virus-hotspot states of New York and New Jersey, 
controlling for the virus spread in the neighboring states, and using deaths from influenza as a 
placebo test. 
This paper finds evidence that supports the potentially protective effect of smoking 
against the novel coronavirus, however, the biological mechanism behind this effect is yet to 
be explored in future research. Currently, the most credible explanation is the anti-
inflammatory and positive immune-modulating effect of smoking attributed to nicotine (e.g., 
Kloc et al. 2020; Polosa and Caci 2020). Nicotine is assumed to make individuals more tolerant 
and less reactive to the infection, and, as a result, they are less likely to experience a cytokine 
release syndrome associated with COVID-19-related high mortality (Garufi et al. 2020). An 
alternative, more surprising explanation is suggested by Changeux et al. (2020), who 
hypothesize that nicotine competes with the virus for binding with the receptors for entry, thus 
decreasing the risk of contracting the decease, but this has not been tested in medical research 
previously.  
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Our paper contributes to the growing literature on smoking and mortality from COVID-
19 by providing the first population-based study with a robust identification strategy that 
employs a novel instrument for smoking. To our knowledge, Mollalo et al. (2020) is the only 
paper that includes smoking prevalence in the US states as a control variable for the spread of 
the novel coronavirus. This paper does control for the endogeneity of smoking and finds no 
significant results. 
Our findings have immediate policy implications. The potential protective effect of 
smoking must be examined more carefully for the purpose of therapy development. Further 
research should evaluate the protective effect of smoking and nicotine using randomized-control 
trials, and the mechanisms behind this effect should be identified and isolated from the direct 
harm of smoking. Additionally, our findings should be taken into consideration before 
advocating the cessation of smoking as an effective measure against the novel virus (e.g., Hefler 
and Gartner 2020). Our results should not be used to promote smoking as it is a direct cause 
of millions of premature deaths worldwide.  
The paper is organized as follows: Section 2 describes the data and the estimation 
strategy; Section 3 presents the main regression results; Section 4 looks at the deaths per capita 
among gender and age groups and provides the results for the placebo tests in the respective 
subgroups using influenza deaths per capita; Section 5 concludes.  
 
2 Data and estimation strategy 
 
The USA is currently a country with the most registered cases and fatalities from the novel 
coronavirus: over 2 million cases and 113 thousand deaths, which constitutes almost 30% of all 
recorded cases and deaths around the world. After the declaration of a national emergency by 
the White House three months ago and the current steady decline of the first wave of the 
pandemic, it might be the right time to assess the determinants of the COVID-19 severity in 
the USA.    
One of the main features of the pandemic in the USA is an uneven geographical 
distribution of the cases and mortality from the virus. We evaluate this regional heterogeneity 
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using the three main indicators of the severity of COVID-19 in each state and map them in 
Figure 1. We use the standard data sources in the COVID-19 literature: Worldometers.info 
and CDC database. First, Panel A of Figure 1 illustrates the differences in the spread of 
registered cases of COVID-19 per thousand population as of June 8, 2020. This measure 
represents mainly the prevalence of symptomatic cases and not the overall rate of infection 
since the asymptomatic cases are substantially underreported (e.g., Manski and Molinari 2020; 
Nishiura et al. 2020). The second measure is the CFR in percentage mapped in Panel B. The 
CFR is a rough approximation of the lethality that may be overstated if actual cases are 
underreported, however, this limitation is of a lesser concern due to the extensive testing in 
the USA.2 An alternative measure of the severity of the COVID-19 is the excess mortality in 
the population of the state, which is a close approximation to the population fatality rate 
(PFR). CDC provides the estimates for the excess mortality as the difference between observed 
mortality between February 1 and June 3 and the expected mortality in the same period based 
on the historical data.3 Panel C shows the excess mortality per thousand population. 
Interestingly, the rate of smoking in the US also varies substantially across the states, as we 
show in Panel D using the recent survey data from the CDC Behavioral Risk Factor 
Surveillance System (BRFSS) measured as a percent of the population that smoked in 2018. 
Can the uneven character of the pandemic be explained by the differences in smoking 
prevalence across the states? For instance, among the three states on the West Coast, the state 
with the highest smoking rates, Oregon, seems to handle the pandemic significantly better than 
its neighbors with fewer smokers, Washington State and California. Does this pattern hold for 
all the states? Figure 2 shows the correlation between smoking rate and the regional COVID-
19 metrics from Figure 1 using scatterplots with linear trends for 49 of the US states, omitting 
isolated states of Hawaii and Alaska. Additionally, Figure 2 includes a scatterplot for overall 
mortality in 2019 to re-confirm smoking as a risk factor for premature deaths in the pre-
pandemic year (e.g., Kontis et al. 2015). 
 
2 While the rate of testing was low during the onset of the pandemic, it has been significantly improved 
shortly after. To this moment, the per capita number of tests in the USA has become one of the highest 
worldwide.  
3 The methodology for calculating the excess mortality and the data are available at the CDC website: 
https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. 
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Figure 1: Differences in COVID-19 severity and smoking rates across the US states 
 
Figure 2: Correlations between the COVID-19 severity and smoking prevalence 
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Panel A of Figure 2 shows a negative relationship between smoking rates and the 
number of cases of COVID-19 in line with the empirical evidence from the hospital-based 
studies. This could be interpreted as fewer overall cases of infection due to the protective effect 
or, most likely, fewer symptomatic cases if people who got sick but did not experience any 
complications refrained from being tested. Panel B shows a negative relationship between 
smoking and the CFR: there are fewer deaths among the registered cases. This potentially 
means that smoking decrease not only the number of symptomatic cases but also the likelihood 
of those cases to have a fatal outcome. Penal C looks at a different measure of fatalities from 
COVID-19 among the population and demonstrates a negative trend: states with fewer smokers 
experienced higher overall human losses. While smoking could be protective against the novel 
virus, it remains the major risk factor for premature deaths as we show in Panel D: the level 
of overall mortality in 2019 was higher in states with more prevalent smoking. 
While illustrative, correlation does not imply causation. We proceed further with the 
regression analysis that addresses the endogeneity of smoking and includes the controls for the 
social and economic characteristics of the states. 
Our estimation strategy is the following:  𝐶𝑂𝑉𝐼𝐷19𝑖 =  𝛼 + 𝛽 𝑆𝑚𝑜𝑘𝑖𝑛𝑔𝑖 + 𝑋𝑖 +  𝜀𝑖,   (1) 
where i indicates the state; COVID19i is the spread or the severity of the decease 
measured by the number of registered cases of COVID-19 per million population in logarithms 
(Covid_Cases), the CFR in percentage (Covid_CFR), and a logarithm of the number of excess 
deaths per million population plus one (Excess_Deaths); Smoking indicates the prevalence of 
smoking in percentage; Xi is the vector of control variables; and i is an error term. 
The data for the first two outcome variable, Covid_Cases, and Covid_CFR, come from 
Worldometers.info, which collects and double-checks the data from federal and subnational 
sources such as CDC and state health departments.4 It was collected on June 8, 2020. The data 
for excess mortality are provided by the CDC. The most recent estimates are available for the 
period from February 1 until June 3.5  
 
4 The methodology is available at the website of Worldometers.info: 
https://www.worldometers.info/coronavirus/about/. 
5 The methodology is available at the CDC website: 
https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. 
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We construct three variables for smoking prevalence. The first two variables are the 
share of the population who smokes (Smoking) and the share of the population who smokes 
daily (Smoking_Daily). The data come from the CDC BRFSS representative survey that has 
interviewed over half a million Americans in 2018. Another variable for smoking is the annual 
cigarette consumption per capita, measured as a logarithm of the number of packs purchased 
in the state per capita (Cigarettes). The data are from the CDC (2018). While cigarette 
consumption is a less precise measure of smoking rates, we use it to show the robustness of our 
results.  
We address the endogeneity of smoking by an instrumental variable approach. Our 
instrument for smoking is motivated by an adverse effect of the state-taxes on cigarette prices, 
and consequently, cigarette consumption. While state-taxes are a common instrument for 
smoking (French and Popovici 2011), they can be themselves endogenous to the state 
characteristics or other state policies. To construct the exogenous instrument, we exploit the 
existence of the state-to-state diffusion of anti-smoking policies (Shipan and Volden 2006). We 
hypothesize that the current cigarette state-tax as a type of anti-smoking policy is affected by 
the past levels of cigarette taxes in the neighboring states. The cigarette taxes of the 
neighboring states from the previous years are orthogonal to the current characteristics of the 
state and influence the smoking rate only via the regional convergence process of cigarette 
taxes and, therefore, our instrument satisfies the exclusion restrictions. 
 Our instrument (Neighbor_Tax) is constructed as an average of state-taxes for a pack 
of cigarettes in the neighboring states calculated for the year 2013 using CDC (2018) data.6 
This allows five years for the tax convergence across the states before our most recent regional 
estimates of smoking. The convergence over this period is considerable: the difference between 
the cigarette tax in the state and its neighbors was 30% smaller in 2018 compared to the same 
difference in 2013.  
We show the effect of our instrument on smoking and cigarette consumption in the 
following regression model:  𝑆𝑚𝑜𝑘𝑖𝑛𝑔𝑖 =  𝑎 +  𝑁𝑒𝑖𝑔ℎ𝑏𝑜𝑟_𝑇𝑎𝑥𝑖2013 + 𝑒𝑖,   (2) 
 
6 Our results are not sensitive to the choice of the year as we show further in a robustness check.  
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where i=1,…,49 indexes the US states, Smoking is the smoking rate in state i, Neighbor_Tax 
is the average state tax on a pack of cigarettes in the year 2013, and e is an error term.  
The control variables include a range of demographic, economic, and political 
characteristics of the US states. We control for the logarithm of the total population 
(Population), population density (Density), the share of the population older than 65 years as 
this group has the highest risk of severe outcomes from COVID-19 (Population_65), the share 
of the population older than 45 years and younger than 65 since this group also has a notable 
fatality rate for COVID-19 (Population_45).7 The additional demographic factor is the share 
of the white population (White) since a few early studies warn about the observed higher risk 
of death among ethnic minorities (e.g., Millett et al. 2020). Among the economic factors, we 
include the average annual per capita income adjusted for the cost of living (Income), inequality 
measured by the Gini coefficient (Inequality), poverty as a share of population under the federal 
poverty line (Poverty). The data from 2018 CDC BRFSS survey allows adding health-related 
factors that might affect the severity of COVID-19: overall healthiness measured as a share of 
people who reported their health condition as excellent (Healthy), and the proportion of 
respondents with body mass index that exceeds 25 (Overweight) since being overweight or 
obese substantially increases the risk of developing complications from COVID-19 (e.g., Cai et 
al. 2020). The non-pharmaceutical interventions were aimed at reducing the spread of 
coronavirus, and, therefore, we control for the overall effect of lockdowns by using the average 
daily percentage of the population that were staying at home (Stayhome). The Stayhome 
variable is constructed from the mobile device location database by Zhang et al. (2020). It is 
an actual estimate of the population that has reduced its mobility between March 1 and May 
31. Finally, we add the party affiliation of the governor (Gov_Republican) if the Republican 
leadership could have affected the local response to the virus outbreak.8   
The summary of variables and the data sources is presented in Appendix A, Table A.1. 
 
7 The population younger than 45 years consitute about 2.5% of all the fatalities, while the population 
between 45 and 64 years old represent 17% of fatalities, and people older than 65 consititute 80.5% of 
all fatalities respectively.  
8 For a discussion one can look into the article of Wall Street Journal available at: 
https://www.wsj.com/articles/why-coronavirus-increasingly-exacerbates-the-red-blue-divide-
11589810871  
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3 Results 
 
Our estimation strategy is based on the variation in smoking prevalence due to our instrument. 
Table 1 presents the first stage of the IV estimation following equation (2) for each proxy of 
smoking, without any control variables and with controls specified in our main estimation 
equation (1). It shows that the average of past cigarette taxes in the neighboring states in 2013, 
Neighbor_Tax, is a strong predictor of a smaller share of active smokers (column 1-2), including 
persistent smokers (column 3-4), and lower cigarette consumption (column 5-6) in 2018. If the 
neighboring states had the cigarette tax higher by one dollar in 2013, that would result in 1.41 
percentage points reduction in smoking rate in 2018. The effect is highly significant in 
estimations with (columns 2, 4, 6) and without control variables (columns 1, 3, 5). The F-
statistics of the first stage above ten indicates strong instruments (Staiger and Stock 1997).  
Table 1: Past state-taxes on cigarettes in the neighboring states and the current prevalence of smoking 
 (1) (2) (3) (4) (5) (6) 
Dep. Variable: Smoking Smoking_Daily Cigarettes 
Neighbor_Tax -2.017*** -1.405*** -1.588*** -1.179*** -0.210*** -0.229*** 
 (-5.42) (-4.05) (-4.93) (-4.25) (-2.87) (-3.25) 
Controls  No Yes No Yes No Yes 
R squared 0.19 0.88 0.15 0.89 0.11 0.76 
F-statistics 29.42 16.38 24.3 18.04 8.26 10.58 
LM test 0.002 0.001 0.003 0.001 0.026 0.004 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49 
 Table 2 presents the main results of our IV estimation for the three indicators of the 
severity of COVID-19 and the overall mortality rate in four panels in an order similar to Figure 
2. Panel A shows that smoking rates have a negative and statistically significant effect on the 
spread of COVID-19 cases in the states. This effect is consistent across all three variables for 
smoking with and without controls. The magnitude suggests that an increase in Smoking by 
one standard deviation would reduce the number of registered infections by 1 percentage points. 
The changes by one standard deviation in Smoking_Daily or Cigarettes yield almost the same 
magnitude of the effect on COVID-19 outcomes. 
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Table 2: The effect of smoking prevalence on the severity of COVID-19 across the US states, IV 
Panel A: Registered cases of COVID-19 per million population, in logs 
 (1) (2) (3) (4) (5) (6) 
Smoking -0.229*** -0.301***     
 (-2.97) (-3.27)     
Smoking_Daily   -0.291*** -0.359***   
   (-3.06) (-3.33)   
Cigarettes     -2.203*** -1.851*** 
     (-2.74) (-2.86) 
Controls  No Yes No Yes No Yes 
Panel B: COVID-19 Case fatality rate, percent 
 (1) (2) (3) (4) (5) (6) 
Smoking -0.782*** -1.001***     
 (-4.53) (-2.83)     
Smoking_Daily   -0.993*** -1.194***   
   (-4.37) (-2.92)   
Cigarettes     -7.510*** -6.153*** 
     (-2.95) (-2.79) 
Controls  No Yes No Yes No Yes 
Panel C: Excess deaths per million population plus one, in logs 
 (1) (2) (3) (4) (5) (6) 
Smoking -0.614*** -0.842**     
 (-2.84) (-2.13)     
Smoking_Daily   -0.779*** -1.004**   
   (-2.85) (-2.30)   
Cigarettes     -5.891** -5.175** 
     (-2.34) (-1.98) 
Controls  No Yes No Yes No Yes 
Panel C: Overall mortality in 2019 per million population, in logs 
 (1) (2) (3) (4) (5) (6) 
Smoking 0.01 0.027***     
 (1.36) (4.26)     
Smoking_Daily   0.013 0.032***   
   (1.38) (4.06)   
Cigarettes     0.099 0.163*** 
     (1.36) (2.89) 
Controls  No Yes No Yes No Yes 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49. 
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 Panel B in Table 2 shows the effect of smoking on the CFR. The higher smoking rate 
is negatively associated with fatality among the registered cases. One standard deviation 
increase in Smoking, Smoking_Daily, and Cigarettes would decrease the CFR by 3.3, 3, and 
2.9 percentage points, respectively. It is important to acknowledge that our estimates are local 
average treatment effects and, thus, they can be larger than the average treatment effect due 
to the heterogeneity in the treatment. The magnitude is striking since smoking reduces not 
only the number of symptomatic cases as has been established in Panel A, but also the share 
of fatalities among these cases.  
 The excess mortality is an important indicator of the overall toll of the pandemic across 
the states. In Panel C, we find that smoking is associated negatively with the rate of excess 
mortality. The magnitude of the one standard deviation increase in Smoking, Smoking_Daily, 
and Cigarettes leads to a reduction in the excess mortality by 2.8, 3, and 2.4 percentage points, 
respectively, which is very similar to the effect size of smoking prevalence on the CFR.  
 Finally, Panel D shows that our variables for smoking prevalence have a positive effect 
on overall mortality in the year before the pandemic, but the effect is statistically significant 
only after we include controls. One standard deviation increase in Smoking is associated with 
0.1 percentage points increase in overall mortality. The finding is in line with the existing 
consensus that smoking causes premature death (e.g., Nam and Rodgers 1998). 
 There are a few interesting correlations between the control variables and the severity 
of COVID-19 that can be observed in Appendix A, Table A.2. For example, COVID-19 is 
relatively more widespread in states with a higher density of population, higher average income, 
and higher poverty rates. The positive correlation between the share of the white population 
and the spread of the infection and its lethality is in line with the findings of Egorov et al. 
(2020) that diverse societies are more likely to follow social distancing guidelines in the times 
of COVID-19 pandemic. A more healthy and less overweight population has a lesser spread of 
the virus, but these parameters are not associated with the fatality rates. Surprisingly, the 
percent of inhabitants staying at home during the pandemic is strongly associated with more 
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cases and deaths from COVID-19, which might be explained by reverse causality when the 
population conforms more to the social distancing in relatively more troubled locations.  
 Our estimation results are robust to several alternative specifications. First, Table A.3 
in Appendix A shows that results do not change if we omit the states of New York and New 
Jersey as potential outliers since they represent the largest outbreaks in the country. Next, we 
test if controlling for the spread and the death toll in the neighboring states affects the results. 
For this purpose, we construct two control variables: one is the logarithm of the average 
number of cases per million population in the neighboring states (Neighbor_Cases), and 
another control is the excess mortality per million population in logarithms 
(Neighbor_Excess_Deaths). Table A.4 in Appendix A shows that the number of infections in 
the neighboring states is positively associated with the number of registered cases in the state, 
but this does not change our main results for smoking. Finally, we test if our results are 
sensitive to the choice of the year for constructing our instrument. We run the same IV 
estimation using the average cigarette state-taxes from 2010 and present the results in Table 
A.5 in Appendix A. The coefficients have the same sign and similar magnitudes as in our main 
estimations. We confirm the robustness of the protective effect of smoking against COVID-19 
once again.  
 
4 Smoking and the fatality of COVID-19 across gender and age  
 
This section investigates the effect of smoking across the gender and age groups. We take 
advantage of the provisional data of confirmed deaths from COVID-19 assembled by the CDC, 
which covers the period from February 1 until June 3, 2020. We expect the protective effect of 
smoking against the virus to be more robust among the male population and less consistent 
among females, especially in the younger age group, since they are less likely to smoke.  
 We aggregate data on all the registered deaths from COVID-19 in four groups by gender 
and by two age categories: older than 65 and older than 45 and younger than 65. We focus 
only on the population older than 45 years old since most (97.5%) of the deaths in the USA 
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occur among this category. We divide each group by the population in the state of the 
respective gender and age and take the logarithm.9 The outcome measures can be interpreted 
as a fatality rate in the respective subgroup of the population. 
 Table 3 provides the results for the mortality among gender and age categories. We 
find the statistically significant protective effect of smoking among both age groups of males 
(Panel A) and older females (Panel B, columns 4-6), but no significant effect among females 
aged between 45-64. The heterogeneity can be explained by a higher proportion of smokers 
among those subgroups. While the gender difference in smoking rates among the older cohorts 
are relatively small (e.g., Waldron 1991; John et al. 2005), younger cohorts of females smoke 
significantly less than older women or men in both groups (e.g., Burns et al. 1997). 
Table 3: Smoking and COVID-19 mortality by age group and gender 
Panel A: Male population 
 (1) (2) (3) (4) (5) (6) 
Dep. Variable: Male COVID-19 deaths 45-64 Male COVID-19 deaths 65+ 
Smoking -0.374**   -0.425***   
 (-2.30)   (-2.91)   
Smoking_Daily  -0.446**   -0.507***  
  (-2.41)   (-3.11)  
Cigarettes   -2.300**   -2.613*** 
   (-2.47)   (-2.67) 
Controls  Yes Yes Yes Yes Yes Yes 
Panel B: Female population 
 (1) (2) (3) (4) (5) (6) 
Dep. Variable: Female COVID-19 deaths 45-64 Female COVID-19 deaths 65+ 
Smoking -0.287   -0.430**   
 (-1.34)   (-2.48)   
Smoking_Daily  -0.342   -0.513**  
  (-1.38)   (-2.56)  
Cigarettes   -1.763   -2.641** 
   (-1.38)   (-2.40) 
Controls  Yes Yes Yes Yes Yes Yes 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49. 
 
 
9 The data on the registered COVID-19 cases cannot be disaggregated by gender and age, and thus we 
are unable to construct the CFR in the respective subgroup of the population.  
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 The CDC’s data allows us to perform a placebo test using the fatalities from influenza 
for the same time period. The main assumption is that smoking does not exhibit any protective 
effect in cases of other respiratory deceases such as influenza and can be even potentially 
harmful (e.g., Bello et al. 2014; Lawrence et al. 2019). We assemble the fatality rate for 
influenza across both genders and the same age groups as in Table 4.   
 The main results in Table 4 suggest that smoking prevalence is not associated with 
lower levels of fatalities from influenza.  On the contrary, all the coefficients are positive, which 
is more in accord with the potentially harmful effect of smoking for respiratory deceases, 
however, they are not statistically significant. 
Table 4: Smoking and influenza mortality by age group and gender 
Panel A: Male population 
 (1) (2) (3) (4) (5) (6) 
Dep. Variable: Male influenza deaths 45-64 Male influenza deaths 65+ 
 (0.74)   (0.43)   
Smoking_Daily  0.125   0.065  
  (0.75)   (0.43)  
Cigarettes   0.644   0.334 
   (0.69)   (0.42) 
Controls  Yes Yes Yes Yes Yes Yes 
Panel B: Female population 
 (1) (2) (3) (4) (5) (6) 
Dep. Variable: Male influenza deaths 45-64 Male influenza deaths 65+ 
Smoking 0.145   0.047   
 (1.32)   (0.46)   
Smoking_Daily  0.173   0.056  
  (1.27)   (0.46)  
Cigarettes   0.894   0.29 
   (1.24)   (0.44) 
Controls  Yes Yes Yes Yes Yes Yes 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49. 
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5 Conclusion 
 
This paper is a first population-based study that investigates the effect of smoking prevalence 
on the spread and the severity of novel coronavirus in the population of the US states. Our 
main finding is the persistent negative relationship between smoking rates and the number of 
registered cases of COVID-19, the CFR, and excess mortality. Our estimation strategy accounts 
for the endogeneity of smoking rates by using past levels of cigarette state-taxes in the 
neighboring states as an instrumental variable, suggesting the causality of the effect. We also 
control for various demographical, economic, and political characteristics of the states and 
perform multiple robustness tests. 
 The protective effect of smoking against COVID-19 is puzzling because today, smoking 
has been consistently proven to be detrimental to individual health in the long-term, and this 
paper also shows that smoking is positively associated with additional mortality. However, for 
most of history, tobacco and smoking have been considered therapeutic and widely used in 
medical practices. Charlton (2004) provides an elaborate historical account of medical uses of 
tobacco since its adoption from the Native American population who considered the herb to 
be the potent remedy against the common cold and fever. In 18th and 19th century Europe, 
tobacco was extensively used against a broad spectrum of infectious deceases as the properties 
of the nicotine were believed to be antiseptic. Therefore, it was not surprising that smoking 
was prescribed by doctors during the massive outbreaks of infections, such as the London 
plague or smallpox outbreak in Bolton (Charlton 2004: 295). Charlton concludes her article 
with a suggestion that “we should set aside the prejudices generated by the ill-effects of tobacco 
smoking and examine the leaves systematically for substances of therapeutic value.“ In the 
times of the COVID-19 pandemic, the persistent evidence for the protective effect of smoking 
makes this suggestion extremely relevant.  
 The purpose of this paper is to provide systematic evidence that would channel the 
efforts of the scientific community for battling the pandemic into investigating the potential 
source of the protective effect of smoking and using it for developing potential treatments 
against COVID-19 and any future coronaviruses.   
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Appendix A 
 
Table A1: Description of the variables and summary statistics 
Variable name Variable description Year Mean St. 
Dev. 
Source 
Covid_Cases Number of registered cases of COVID-19 per million population in 
logarithms (as of June 8, 2020) 
2020 8.38 0.76 [1] 
Covid_CFR Case fatality rate, % (as of June 8, 2020) 2020 4.3 1.97 [1] 
Excess_Deaths Number of estimated excess deaths in the period between February 
1 and June 3 cases per million population plus one, in logarithms 
2020 3.58 2.16 [2] 
Mortality Number of deaths per million population, in logarithms 2019 9.09 0.14 [3] 
Smoking Share of population who smoke, % 2018 16.61 3.33 [4] 
Smoking_Daily Share of population who smoke daily, % 2018 11.73 2.99 [4] 
Cigarettes The logarithm of packs of cigarettes purchased over the year per 
capita 
2018 3.63 0.47 [5] 
Cigarette_Tax State tax for the pack of cigarettes, in dollars 2018 1.7 1.11 [5] 
Neighbor_Tax Average state-taxes for the pack of cigarettes in the neighboring 
states in 2013, in dollars 
2013 1.39 0.72 [5] 
Population Logarithm of population 2019 15.23 1.03 [3] 
Population_65 Share of population older than 65  2018 16.46 1.87 [3] 
Population_45 Share of population in the age between 45 and 64 2018 25.65 1.8 [3] 
Density The logarithm of people per square mile 2020 4.72 1.43 [3] 
White An estimated share of the white population, % 2017 69.21 15.1 [3] 
Income Average annual income adjusted for the cost of living 2019 10.88 0.11 [6] 
Inequality Gini index, average over 2013-2017 years 2017 46.63 1.99 [3] 
Poverty Percentage of population living below the federal poverty line,  
average over 2013-2017 years 
2017 0.14 0.03 [3] 
Healthiness Share of the surveyed population who report an excellent state of 
health 
2018 17.62 2.36 [4] 
Overweight Share of the surveyed population who report their BMI being over 
25 
2018 66.31 3.37 [4] 
Stayhome Percentage of residents staying at home for the period March 1 – 
May 31 
2020 0.28 0.05 [7] 
Gov_Republican A dummy that equals one if the governor of the state is a 
Republican 
2020 0.51 0.51 [8] 
Sources:        [1] Worldometer.info 
    
[2] CDC 
    
[3] US Census Bureau 
    
[4] CDC: BRFSS  
    
[5] CDC: State Tobacco Activities Tracking and Evaluation  
    
[6] Bureau of Economic Analysis 
    
[7] Maryland Transportation Institute  
    
[8] Ballotpedia  
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Table A.2: The effect of smoking prevalence on the severity of COVID-19 with controls 
 (1) (2) (3) 
Dep. Variable: Covid_Cases Covid_CF Excess_Deaths 
Smoking -0.301*** -1.001*** -0.842** 
 (-3.27) (-2.83) (-2.13) 
Population -0.354*** -0.498 -0.507 
 (-3.65) (-1.25) (-1.14) 
Population_65 -0.112** -0.247 -0.257 
 (-2.01) (-1.56) (-1.41) 
Population_45 0.11 0.944*** 0.831*** 
 (1.56) (3.92) (3.11) 
Density 0.236*** 0.113 0.505 
 (2.83) (0.31) (1.52) 
Income 3.366*** 9.799*** 11.014*** 
 (4.84) (3.20) (3.36) 
Inequality 0.062 0.04 -0.456 
 (0.86) (0.11) (-1.04) 
Poverty 0.148* 0.962** 0.949** 
 (1.74) (2.57) (2.37) 
Healthiness -0.143* -0.334 -0.245 
 (-1.89) (-0.97) (-0.65) 
Overweight 0.150** 0.231 0.224 
 (2.23) (0.99) (0.85) 
White 0.021* 0.127*** 0.053 
 (1.69) (2.62) (1.07) 
Gov_Republican -0.048 -0.036 0.737 
 (-0.28) (-0.07) (1.24) 
Stayhome 0.082*** 0.336** 0.349** 
 (2.64) (2.43) (2.48) 
R2 0.588 0.248 0.36 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49. 
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Table A.3: Robustness check, exclusion of states of New York and New Jersey 
 (1) (2) (3) 
Dep. Variable: Covid_Cases Covid_CFR Excess_Deaths 
Smoking -0.272*** -1.137*** -0.912** 
 (-2.71) (-3.04) (-2.03) 
Controls  Yes Yes Yes 
F-statistics 16.69 16.69 16.69 
LM test 0.001 0.001 0.001 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=47. 
 
Table A.4: Robustness check, controlling for the neighboring spread of COVID-19 cases and 
excess mortality 
 (1) (2) (3) 
Dep. Variable: Covid_Cases Covid_CFR Excess_Deaths 
Smoking -0.216*** -0.999*** -0.721* 
 (-2.79) (-2.64) (-1.79) 
Neighbor_Cases 0.650** -0.192 1.17 
 (2.05) (-0.14) (1.02) 
Neighbor_Excess 
Deaths 
-0.122 0.085 -0.277 
 (-1.01) (0.18) (-0.68) 
Controls  Yes Yes Yes 
F-statistics 12.62 12.62 12.62 
LM test 0.004 0.004 0.004 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49. 
 
Table A.5: Robustness check, using different year for neighboring cigarette-taxes (2010) 
 (1) (2) (3) 
Dep. Variable: Covid_Cases Covid_CFR Excess_Deaths 
Smoking -0.302*** -0.935*** -0.898** 
 (-3.56) (-2.84) (-2.26) 
Controls  Yes Yes Yes 
F-statistics 18.29 18.29 18.29 
LM test 0.001 0.001 0.001 
Notes: t statistics in parentheses, * p < 0.1, ** p < 0.05, *** p < 0.01. Number of states N=49. 
 
